Robust go/no-go decision-making is essential for effectively managing risk across a clinical portfolio. In early phase development, it is particularly important to have the correct tools in place to terminate ineffective compounds quickly, while accelerating promising ones through the process.
AstraZeneca established a quantitative standard decision-making framework across its Early Clinical Development group. While the system was working successfully, AstraZeneca sought to further enhance the efficiency of the existing process by reducing the burden for statisticians, who were creating their own code to generate the required decision plots. The team required a software tool that could create standardized outputs to streamline communication, save time, and extend the framework with additional features. They needed a development partner with the unique statistical and software development expertise to ensure that:
-James Matcham, Head of Early Clinical Development Biometrics, AstraZeneca.
Cytel Strategic Consulting assigned an expert team of statisticians and software developers to work closely with AstraZeneca counterparts.
The software is developed as a web-based platform using a Windows based server for statistical computations ensuring flexibility for AstraZeneca users who are able to access the tool via a standard internet browser.
Cytel statisticians worked in collaboration with AstraZeneca statisticians to accommodate a Bayesian as well as Frequentist approach within the software interface, extending the established framework.
The software supports various therapeutic areas with a diverse set of clinical endpoints (normal, binomial, survival), as well as different types of interim analyses.
The introduction of validated software saves time for AstraZeneca statisticians and statistical programmers in creating and validating their own code.
The creation of consistent, presentation quality decision plots eases communication between stakeholders and ensures a standardized approach.
The user-friendly software interface has positively impacted the way the statistician and other clinical stakeholders work and the speed at which decisions can be made. For example, if, during a meeting, there is a question about the impact of a change in study parameters, it can be assessed with the software and discussed immediately during the meeting. This eliminates the need for the statistician to go back and program new criteria, create slides and arrange follow-up discussions.
The Cytel Advantage
At Cytel we are committed to helping our pharmaceutical, biologic and medical device clients make better decisions, faster and improve clinical development success rates. Leading industry, academic and regulatory organizations around the world rely on our validated technology solutions, expert statistical consulting, and efficient clinical research services. Combining biostatistics expertise with programming talent, Cytel software collaborations deliver practical, user-friendly tools to power clinical trial innovation.
A quantitative go/ no-go decision-making framework allows studies to be designed from the outset with the program development decision in mind.
AstraZeneca’s approach is based on a method proposed by Lalonde et al (1) and extended by Frewer et al (2). This 3 outcome framework is built on Go/ No- Go and Consider zones, and uses the input of various decision parameters to generate Go and Stop criteria. Based on these criteria standard decision plots are created.